Source comparison
BPC-157 for Lyme Disease Research — Comparison of Therapeutic Targets
Bacterial clearance Doxycycline/amoxicillin achieve 85–95% spirochete eradication in early-stage Lyme No direct antimicrobial activity. BPC-157 does not kill Borrelia burgdorferi Antibiotics remain first-line; peptide targets post-clearance pathology Neuroinfl
This comparison does not assign a generated winner or score.
- Bacterial clearance
- Doxycycline/amoxicillin achieve 85–95% spirochete eradication in early-stage Lyme
- No direct antimicrobial activity. BPC-157 does not kill Borrelia burgdorferi
- Antibiotics remain first-line; peptide targets post-clearance pathology
- Neuroinflammation
- No direct anti-inflammatory mechanism; relies on immune resolution post-eradication
- Reduces TNF-α and IL-6 by 40–60% in preclinical models; stabilises blood-brain barrier
- Addresses cytokine-driven PTLDS symptoms antibiotics leave untreated
- Tissue repair
- No regenerative properties; healing depends on endogenous repair capacity
- Upregulates VEGF and FAK-paxillin signalling; accelerates axonal and vascular regeneration by 35% in animal models
- Supports neural and connective tissue recovery in chronic cases
- Duration of effect
- Single course (10–28 days); no residual therapeutic action post-completion
- Research protocols typically run 28–60 days; effects on tissue repair may persist beyond administration window
- Peptide may offer extended recovery benefit in refractory PTLDS
- Safety profile
- Well-established; adverse events limited to GI disturbance and photosensitivity
- Preclinical safety demonstrated across 40+ studies; no severe adverse events reported in animal models
- Human safety data limited to small case series; formal clinical trials needed
- Bottom Line
- Antibiotics are non-negotiable for active infection but offer no mechanism for resolving inflammatory or structural damage post-clearance
- BPC-157 addresses the inflammatory and regenerative gaps antibiotics leave, making it a plausible adjunct in refractory PTLDS cases under research settings